News Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
0.524 ^USD	-3.23%		-6.60%	-50.57%

21/03	Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
15/03	Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ensysce Biosciences Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published	22/04	AQ
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	10/04	AQ
Ensysce Biosciences : Corporate Overview	28/03	PU
Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024	21/03
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Ensysce Biosciences Receives Positive Nasdaq Listing Determination	28/02	AQ
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	21/02	CI
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	15/02	CI
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds	14/02	AQ
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference	07/02	AQ
Ensysce Shares Rally After FDA Feedback on Pain Medication	31/01	DJ
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	31/01	CI
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting	26/01	AQ
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR	24/01	AQ
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	24/01	DJ
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	23/01	MT
Ensysce Biosciences Issues 2024 Shareholder Letter	09/01	AQ
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023	20/12	AQ
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic	15/12	AQ
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	14/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Summary

Filters